Hyperlipidemia

17-22 of 22

• 

  RestartResume

  Reaching LDL-c targets in patients at high CV risk: How well are we doing?

  RestartResume

  Reaching LDL-c targets in patients at high CV risk: How well are we doing?

  MinuteCE®

  Reaching LDL-c targets in patients at high CV risk: How well are we doing?

  Julia Brandts, MD

  0.75 program credits

  • 

    

    Julia Brandts, MD

  0.75 program credits

• 

  MinuteCE®

  Clinical choices in managing LDL-c: Where do novel therapies fit in?

  Kausik Ray, MBChB, MD, MPhil; Julia Brandts, MD

  0.75 credits 4 episodes

  • 

    

    Kausik Ray, MBChB, MD, MPhil

  • 

    

    Julia Brandts, MD

  • 

    

    Pasquale Perrone-Filardi, MD, PhD

  • 

    

    Ulrich Laufs, MD, PhD

  0.75 credits 4 episodes

• 

  MinuteCE®

  Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target

  Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma; Stephen Nicholls, FRACP, FACC, FESC, FAHA

  0.50 credits 3 episodes

  • 

    

    Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  • 

    

    Stephen Nicholls, FRACP, FACC, FESC, FAHA

  • 

    

    Erin Michos

  0.50 credits 3 episodes

• 

  RestartResume

  CETP inhibition: Lessons from two decades of clinical trials

  RestartResume

  CETP inhibition: Lessons from two decades of clinical trials

  MinuteCE®

  CETP inhibition: Lessons from two decades of clinical trials

  Stephen Nicholls, FRACP, FACC, FESC, FAHA

  0.50 program credits

  • 

    

    Stephen Nicholls, FRACP, FACC, FESC, FAHA

  0.50 program credits

• 

  RestartResume

  A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?

  RestartResume

  A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?

  MinuteCE®

  A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?

  Erin Michos

  0.50 program credits

  • 

    

    Erin Michos

  0.50 program credits

• 

  RestartResume

  What do we know now that could have changed the history of CETP inhibition?: genetics and biology   

  RestartResume

  What do we know now that could have changed the history of CETP inhibition?: genetics and biology   

  MinuteCE®

  What do we know now that could have changed the history of CETP inhibition?: genetics and biology   

  Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  0.50 program credits

  • 

    

    Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  0.50 program credits